EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
|
|
- Shannon Flynn
- 5 years ago
- Views:
Transcription
1 EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane
2 HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9 countries around the world. Two of these involved vaccine candidates that entered Phase II trials, an intermediate stage of clinical evaluation. Several of those newly initiated trials involved novel vaccination strategies Participation by Africa in those trials is continuously increasing with Rwanda started its first AIDS vaccine and South Africa began the country s first Phase II AIDS vaccine trial
3 PROGRESS IN NUMBER OF COUNTRIES PARTICIPATING IN VACCINE TRIALS country 8 countries participating in vaccine trials
4 CLINICAL TRIAL SITES IN AFRICA PARTICIPATING IN HIV VACCINE TRIALS Kampala, Uganda Kayunga, Uganda Mulago, Uganda Entebbe, Uganda Masaka, Uganda Kigali, Rwanda Lusaka, Zambia Gabarone, Botswana Kericho, Kenya Kilifi, Kenya Kisumu, Kenya Nairobi, Kenya Dar es Salaam, Tanzania Blantyre, Malawi Medunsa,SA Mbeya, Tanzania Soweto, SA Cape Town, SA KOSH,SA Durban, SA Active Pending
5 PROGRESS IN NUMBER OF COUNTRIES PARTICIPATING IN VACCINE TRIALS Countries currently involved in vaccine trials Countries preparing for vaccine trials
6 COMPLETED TRIALS IN AFRICA* Phase Trial Name/ Sponsor Country ALVAC205 (Pasteur Merieux): Gag, pol, env (Subtype B) Status Phase I (40) DAIDS Uganda Complete DNA Plasmid (Polyepitope Pharmexa Epimmune): Polyepitope Phase I (42) HVTN/DAIDS Botswana Complete DNA MVA (Oxford / IAVI): Gag, polyepitope (Subtypes A) Phase II (238) IAVI Kenya, Uganda, South Africa Complete VEE Replicon (AlphaVax): Gag (Subtype C) Phase I (88) HVTN/DAIDS South Africa, Botswana Complete Ad 5 (Merck): Gag (Subtype B) Phase II (120) HVTN/DAIDS South Africa, Malawi Complete *follow-up still ongoing
7 Phase PREVENTIVE VACCINE CONCEPTS IN TRIAL IN AFRICA Trial Name/ Sponsor Country Status Adeno Associated (TG, IAVI): Gag-Pr-RT (Subtype C) Phase II (90) IAVI Uganda, Zambia, South Africa Enrolling DNA prime/ Ad5 boost (VRC): Gag, Pol, Nef, Env (Subtypes A,B,C) Phase II (114) IAVI V001, VRC/DAIDS Rwanda, Kenya Enrolling Phase II (240) HVTN 204, VRC/ DAIDS South Africa Enrolling Phase II (324) RV172,WRAIR VRC/DAIDS Uganda, Kenya, Tanzania Enrolling
8 Phase PREVENTIVE VACCINE CONCEPTS IN TRIAL IN AFRICA Trial Name/ Sponsor Ad5 (Merck): Gag-Pol-Nef (Subtype B) Country Status IIb (3000) HVTN503, Merck/DAIDS South Africa Pending DNA, MVA: Gag, RT, env, pol (Subtype A, E) II (60) SIIDC, Karolinska, EU,Sida/SARE C Tanzania Pending ALVAC-HIV vcp1521: Gag, Pro, Env (Subtype B, E) I (50) Perinatal HPTN027/ DAIDS Uganda Pending
9 FIRST TEST OF CONCEPT TRIAL IN AFRICA (Q4 2006): MRKAd5 Trivalent Vaccine ITR L ψ hcmv gag pa MRKAd5 HIV-1 gag ITR R ITR L ψ hcmv pol pa MRKAd5 HIV-1 pol ITR R ITR L ψ hcmv nef pa MRKAd5 HIV-1 nef ITR R ΔE1 1:1:1 mixing of 3 vectors G. Gray, PHRU, SA
10 FIRST TEST OF CONCEPT TRIAL : HVTN 503 A South African Study to test subtype B vaccine (Ad5 gag, pol, nef) in subtype C region (similar to STEP HVTN502 in MSM in USA): Will subtype B vaccine be efficacious against subtype C heterosexual infection Markedly enhance the information on efficacy in women Refine the assessment of the impact of pre-existing Ad5 titers More than double the number of endpoints to enhance the evaluation of correlates of protection. Adapted from G. Gray, PHRU, Soweto
11 VRC DNA PRIME RAD5 BOOST Currently largest trial concept being tested in Africa Enrolling into 3 trials /6 countries in Africa >600 participants Involving 3 major vaccine initiatives /networks. HIV Vaccine Trials Network (HVTN) US Military HIV Research Program (USMHRP) International AIDS Vaccine Initiative (IAVI) PAVE 100 (in planning fo 2007/8) will be next proof of concept trial in Africa planning to enrol ~12,000 globally and ~8,000 in Africa
12 THERAPEUTIC VACCINE CONCEPTS IN TRIAL IN AFRICA Phase Sponsor Country Status DNA Plasmid: Tat, rev, nef, gag, pol, env (Subtype B) Phase II (60) FIT Biotech South Africa Enrolling Tat Protein: (Subtypes B) Phase II (60) AVIP /ISS South Africa Enrolling E. Vardus, PHRU, SA
13 PLANNED VACCINE TRIALS PAVE 100: DNA /Ad5; ~ participants; in Africa; multiple sites; multiple partners. Mrk Ad5: Adolescent trial in SA (HVTN/DAIDS) SAAVI DNA /MVA: Phase I trial in SA (SAAVI / HVTN /DAIDS) EuroVac (NYVAC) Chiron (Subtype C Env) Tat Vaccine (AVIP /ISS)
14 INCREASING PARTICIPATION BY AFRICA > volunteers? 12 countries 50 volunteers 1 country 400 volunteers 8 countries 15 trial sites 2010 > volunteers
15 SCIENTIFIC CHALLENGES SPECIFIC TO AFRICA Vaccine Pipeline is too narrow Pre-existing immunity to vaccine vector Genetic Diversity
16 Osmanov, pers. comm
17 «ARV therapy in sub saharan Africa : -Complicated combination regimens -Expensive and dangerous -Severe side effects -Rapid development of drug resistance in the community». Instead of promoting expensive and dangerous ARV therapies PREVENTION» Lancet,1998
18 SHORT TERM EVALUATION ON THE FIRST 175 PATIENTS Virological and immunological results similar to Western countries Excellent Adherence Good Accessibilty and Acceptability
19 CLINICAL TRIALS IN AFRICA Access to ARV for HIV-infected individuals in resource-poor settings Efficacy? Safety? Adherence? Potent, safe, inexpensive simplified regimen
20 Once a day DDI/3TC/EFV regimen in treatment naive HIV-1 1 infected adults in Senegal ANRS / IMEA 011 study (1999) R.LANDMAN 1, R.SCHIEMANN 1, S.THIAM 2, A.CANESTRI 1, M.VRAY 4, C.DALBAN 4 E. DELAPORTE 3, S. MBOUP 2, PS. SOW 2, MA. FAYE NIANG 2,PM. GUEYE 2, G. PIEL 4, G. PEYTAVIN 1, S. BADIANE 2, PM. GIRARD 1, JP. COULAUD 1, I. NDOYE 2, AIDS 2003
21 Once a day HAART regimen in treatment naive HIV-1 infected adults in Senegal ANRS / IMEA 011 study Evolution from baseline of viral load and CD4 count Δ VL log10 copies/ml months 6 months 12 months 15 months Δ CD4 cells/mm ,2-3,5-3,5-3,
22 HIV and non HIV pathologies / IMEA 011 % Path VIH % Path non VIH J0 S2 M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
23 CLINICAL TRIALS in Africa 1. First trial in Africa of a simplified regimen 2. effective through treatment period among severely immunocompromised individuals in resource-poor settings 3. ARV clinical trial in resource-poor settings feasible 4. Introduction et validation of new ARV Drug in SENEGAL
24 ONGOING TRIAL ANRS 1207/IMEA 025: Once a day Tenofovir/Emtricitabine/Efavirenz regimen (3 pills)
25 Viral load ANRS 1207/IMEA ,8-3,6-3,6 JO (N=40) M1 (N=39) M3 (N=37) M6 (N=32) Série1 0-2,8-3,6-3,6
26 Preliminary results : ANRS 1207/IMEA 025 Good virological and immunological efficacy Good adherence to treatment More simplified regimen 2 daily pills Truvada (TDF/FTC)+EFV 1 daily pill TDF/FTC/EFV)
27 ATRIPLA : TDF+FTC+EFV 1 daily pill TRUVADA + SUSTIVA = ATRIPLA Mathias A., IAC 2006, Abs. TUPE0098
28 Research Clinical Center, Fann
29 HIV LABORATORIES AT LE DANTEC
30 HIV LABORATORIES AT LE DANTEC
31 CONCLUSION (1) Increased African participation in vaccine trials Increased funding to address scientific questions Increased partnerships to accelerate the field Increased success rate at an accelerated pace (Results of first IIb trials in Africa still 3-5 years)
32 CONCLUSION (2) ARV scaling up in developing countries Host, viral,environmental factors ( logistical, operational etc..) Affordable second line regimen required Need of incresing African participation in ARV clinical trials Impact in developing and developed countries
33 ACKNOWLEDGEMENTS WILLIAMSON C DELAPORTE E SOW SALIF
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationOngoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
More informationOngoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)
HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype
More informationNovel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationACCELERATING THE GLOBAL EFFORT FOR HIV VACCINE RESEARCH
WHO/IVB/06.07 ÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆ ACCELERATING THE GLOBAL EFFORT FOR HIV VACCINE RESEARCH Af r i c a Af r i c a A LITTLE C ACCELERATING THE GLOBAL EFFORT FOR HIV VACCINE
More informationLearning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda
Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda Pontiano Kaleebu MRC-UVRI Uganda Research Unit on AIDS & UVRI-IAVI HIV Vaccine Programme Past 1987 Cohort studies
More informationPartners in Prevention Lessons Learned Importance of Network Culture & Feedback Relevance for MTN
Partners in Prevention Lessons Learned Importance of Network Culture & Feedback Relevance for MTN MTN Annual Regional Meeting, Cape Town September 2008 Connie Celum, MD, MPH Clinical trials require. Important,
More informationStart Date* Sites Description
HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationThe History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationStart Date* Sites Description
076 17 083 180 084 100 085 90 098 94 Inovio rad35 clade A clade A rad clade B clade B PENNVAX-GP IL-12 adjuvant September-11 Seattle The study looks at the immune response of genital and rectal tissues
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationEnrollment of high risk men in Africa
Enrollment of high risk men in Africa Susan Allen MD MPH Professor, Department of Pathology and Laboratory Medicine Emory University Rwanda Zambia HIV Research Group Africa Population 950 million by Region
More informationThe Potential For Harnessing the Immune System to Control HIV
The Potential For Harnessing the Immune System to Control HIV Gordon Dickinson, MD Chief, Infectious Diseases, U Miami School of Medicine, and Co-Director, Special Immunology, Miami VA Medical Center The
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationHIV treatment trials using novel strategies and drug combinations
SECOND JOINT CONFERENCE OF BHIVA AND BASHH 2010 Dr Sheena McCormack MRC Clinical Trials Unit, London 20-23 April 2010, Manchester Central Convention Complex HIV treatment trials using novel strategies
More informationExpansion of Kangemi Clinic Project Budget & IAVI s Mission and Activities
Let us not underestimate the resources required to conduct this battle. In this inter-dependent and globalised world, we have indeed again become the keepers of our brother and sister. That cannot be more
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More informationHVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
More informationHIV vaccine research and development
HIV vaccine research and development What is an HIV vaccine and how does it work? An HIV vaccine is a substance given to the body to teach it to defend itself against HIV. A successful preventative HIV
More informationUSA, Peru, Brazil I 01-I-0079 Completed VRC4302 DNA USA I 04/ Completed APL
Phase Trial D Status Prime Boost 1 Boost 2 Strategy Location HVTN 117 VA Ongoing Ad26.Mos.HV Ad26.Mos4.HV gp140 C Rwanda C89220HPX200 4 Trivalent Vector -, b HVTN 704 AMP Ongoing VRC-HVMAB0 60-00-AB Passive,
More informationThe Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa
The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa HPTN 075 Protocol Chair: Theo Sandfort New York State Psychiatric Institute and Columbia University
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationTrial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationImpact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017
Impact of the Proposed Cuts to HIV/AIDS Research Kevin Fisher AVAC September 7, 2017 President s FY18 Budget Cuts $544 m from the FY 2017 NIH HIV/AIDS research budget levels A cut of 18.5% FY 18 Cut FY
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationAccelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges
Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges George Siberry, MD, MPH OGAC Senior Technical Advisor for Pediatrics March, 2016 Compared to Adults, Children (
More informationMTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012
MTN-020 and IPM 027 and the MTN-020 DSMB Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 Developing a range of options for antiretroviral-based HIV prevention Pill
More informationHPTN 052. Myron S. Cohen, MD Principal Investigator. Presented at the 6 th Int. Workshop on HIV Transmission, July 2011, Rome, Italy
HPTN 052 Myron S. Cohen, MD Principal Investigator Presented at the 6 th Int. Workshop on HIV Transmission, 14 15 July 2011, Rome, Italy Antiviral Treatment as Prevention Extensive biological plausibility
More informationMay HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationEfficacy Results from the Step Study
Efficacy Results from the Step Study (Merck V520 Protocol 023/HVTN 502) A Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine CROI February 5, 2008 Boston, MA Rationale for
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationAn Update on the HIV Prevention Landscape: The Role of Combination Prevention
1 An Update on the HIV Prevention Landscape: The Role of Combination Prevention Susan Buchbinder, MD Bridge HIV, SFDPH; UCSF MTN Regional Meeting October 29, 2013 2 Overview 1. Why combination prevention?
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationPreparations for HIV Vaccine Research at Zambia-Emory HIV Research Project (ZEHRP)
Preparations for HIV Vaccine Research at Zambia-Emory HIV Research Project (ZEHRP) William Kilembe 1, Susan Allen 1,2, Elwyn Chomba 3, Cheswa Vwalika 1, Shabir Lakhi 1,3, Olivier Manigart 1, Patricia Fast
More informationHIV In South Africa: Turning the Tide of the Epidemic
HIV In South Africa: Turning the Tide of the Epidemic Jean B. Nachega, MD, PhD Associate Professor Department of Epidemiology Pittsburgh University, Graduate School of Public Health E-mail: JBN16@PITT.EDU
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationAIDS in Africa. An Update. Basil Reekie
AIDS in Africa An Update Basil Reekie Contents General Statistics The trend of HIV in Africa Ugandan experience UNAIDS 2006 Latest African Statistics by Country HIV Intervention Light at the end of the
More informationCurrent VISP/R Practices Overview
Vaccine-Induced Sero-Positivity/ Sero-Reactivity(VISP/SR) Current VISP/R Practices Overview Mary A. Allen, R.N. M.S. National Institute of Allergy and Infectious Diseases National Institutes of Health,
More informationT W O D E C A D E S, O N E M E S S A G E : P R E V E N T I O N M AT T E R S
8 7 6 5 4 3 2 1 V 7 YEARS AND COUNTING... VI IV III II AVAC? 4 to an AIDS Vaccine? 3 2 AIDS VACCINE ADVOCACY COALITION MAY 2001 AIDS VACCINE ADVOCACY COALITION MAY 2000 1 HOW DO YOU FIGHT A DISEASE OF
More informationFactors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa
Factors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa Dvora Joseph Davey 1, 2, PhD, Zulfa Abrahams 2, PhD 1 BroadReach, South Africa
More informationFaculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationSocio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania
Socio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania Dr. Fausta Franklin Mosha (MD, MSc, MSc, PHD) Ministry of Health and Social Welfare 22 nd October
More informationAffordable tests for HIV drug resistance and HIV viral load in Africa Prof Tobias Rinke de Wit
Affordable tests for HIV drug resistance and HIV viral load in Africa Prof Tobias Rinke de Wit 6 th INTEREST Workshop Mombasa, Kenya, May 8-11, 2012 The roll-out of ART in resource poor settings has followed
More informationCurrent challenges of paediatric HIV care Experiences in Sub-Saharan Africa. Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya
Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya Current Challenges of Paediatric HIV Care What is Happening in the
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationTreatment as Prevention
Optimizing the Impact of ART Treatment as Prevention A Made-in-BC Strategy to End the AIDS Pandemic Julio Montaner, OC, OBC, MD Professor of Medicine and Head, Division of AIDS, University of British Columbia
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationRichard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pre-exposure prophylaxis (PrEP)
More informationGlobal AIDS New Developments in Care
Global AIDS New Developments in Care Royce C. Lin, MD Assistant Clinical Professor of Medicine scope pledge delivery future Adults and children estimated to be living with HIV, 2005 Western & Eastern Europe
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationHIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง
HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationAIDS killed 2.5 million people in 2007.
HIV Vaccines: Time for a New Vision Annie De Groot MD EpiVax GAIA Vaccine Foundation Brown University and now... Institute for Immunology and Informatics, University of Rhode Island University i of Georgia
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationPrevention and care towards vulnerable and stigmatized populations (MSM, drug users, sex workers)
Prevention and care towards vulnerable and stigmatized populations (MSM, drug users, sex workers) Joseph LARMARANGE - CEPED/IRD Symposium ANRS - AIDS 2012-23 July 2012 Epidemiological context» South America
More informationASLM Building laboratory capacity in Africa in a sustainable way
ASLM Building laboratory capacity in Africa in a sustainable way Tsehaynesh Messele, PhD ASLM, Chief Executive Officer Annual AMDS meeting September 29-30, 2014 Geneva Laboratory capacity gaps in Africa
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationTasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
More informationQuestions and answers: HVTN 084 vaccine trial
1. What is the HVTN 084 trial? Questions and answers: HVTN 084 vaccine trial Version 2 Last updated December 2, 2010 HVTN 084 is the name of a clinical trial to test the safety of 2 experimental HIV vaccines.
More informationLetter from the CEO. Dear Friends of IAVI,
IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationPRACTICE POINTS AIDS Vaccine 2001: Looking to the Future
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future 1 Ronald T. Mitsuyasu 1 Associate Professor of Medicine, University of California Los Angeles, and Director of the UCLA CARE Center, UCLA Medical
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationBuilding Long-term Capacity for HIV/AIDS in Africa: S-S and Regional Strategies
Building Long-term Capacity for HIV/AIDS in Africa: S-S and Regional Strategies Quarraisha Abdool Karim, PhD Director: CU-SA Fogarty AITRP Institute of Medicine (IOM) Envisioning a Strategy to Prepare
More informationCD4 WORKSHOP REPORT JULY 22, 2017
CD4 WORKSHOP REPORT JULY 22, 2017 TABLE OF CONTENTS Contents Introduction 1 Strengthening the interface between diagnostics and care treatment monitoring 2 Findings from the first regional CD4 workshop
More informationWorking to End the HIV Pandemic: Glimmers of Hope. Transmission of HIV-1 Biological Requirements
Working to End the HIV Pandemic: Glimmers of Hope Myron S. Cohen, MD Director, Institute for Global Health The University of North Carolina Transmission of HIV-1 Biological Requirements Infectious Inoculum
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationSAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
More informationUnited Nations Millennium Declaration: the 8 Millennium development Goals
CIH Strategy To develop strong research clusters within specific health research areas in fields of global importance, and to contribute to improvement of health policy (support, care and prevention/health
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationPREVENTION OF HIV-1 Infection. Myron S. Cohen, MD Institute for Global Health The University of North Carolina
PREVENTION OF HIV-1 Infection Myron S. Cohen, MD Institute for Global Health The University of North Carolina University of North Carolina 6/3/2012 Telling A Story A beginning A middle We ABSOLUTELTY don
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationFAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030
Evidence informed, responsive and sustainable care FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030 Alti Zwandor UNAIDS Country Director Maseru, Lesotho 9 December
More informationWhere We Have Been and Where We are Going. Ian McGowan MD PhD FRCP
Where We Have Been and Where We are Going Ian McGowan MD PhD FRCP Directions Where we were Where we are headed Where we are 2005 The size of your dreams must always exceed your current capacity to achieve
More informationHormonal contraception and HIV disease progression: a multi country analysis of the
Hormonal contraception and HIV disease progression: a multi country analysis of the MTCT Plus cohort Stringer EM, Sinkala MS, Giganti MG, Carter R, Toro P, El Sadr W, Stringer JSA, Abrams E Hormonal Contraception
More informationSocial and Behavioral Research in HVTN
Social and Behavioral Research in HVTN Michele P. Andrasik The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases HVTN MISSION To fully characterize
More informationFHI Study 10015: FEM-PrEP
FHI Study 10015: FEM-PrEP Phase 3, multi-center, double-blind, randomized, placebo-controlled effectiveness and safety study to assess the role of Truvada in preventing HIV acquisition in women MTN Annual
More informationProgress Towards the Child Mortality MDG in Urban Sub-Saharan Africa. Nyovani Janet Madise University of Southampton
Progress Towards the Child Mortality MDG in Urban Sub-Saharan Africa Nyovani Janet Madise University of Southampton United Nations Expert group Meeting on Population Distribution, Urbanization, Internal
More informationiavi Imagine a world without AIDS HIV Vaccine Translational Research Laboratory International AIDS Vaccine Initiative
HIV Vaccine Translational Research Laboratory Imagine a world without AIDS International AIDS Vaccine Initiative www.iavi.org info@iavi.org Translational Health Science and Technology Institute www.thsti.res.in
More informationA smart and doable investment
90-90-90 A smart and doable investment As of December 2013 Adults and children living with HIV Adults and children newly infected Adult & child deaths due to AIDS 35.0 million [33.2 million 37.2 million]
More information